Entrada Therapeutics (TRDA) Deferred Taxes (2020 - 2021)
Entrada Therapeutics' (TRDA) quarterly Deferred Taxes came in at $57000.0 in Q4 2021, up 272.73% year-on-year from $15292.7 in Q4 2020, and up 125.68% quarter-over-quarter from -$222000.0 in Q3 2021.
Entrada Therapeutics (TRDA) Deferred Taxes (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $57000.0 for Q4 2021.
- On a quarterly basis, Deferred Taxes rose 272.73% year-over-year to $57000.0 in Q4 2021; TTM through Jun 2022 was -$165000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $396000.0, up 628.0% from the prior year.
- Deferred Taxes rose to $57000.0 in Q4 2021 per TRDA's latest filing, from -$222000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $502000.0 in Q1 2021 and bottomed at -$222000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 57,000.00 |
| Sep 30, 2021 | -222,000.00 |
| Jun 30, 2021 | 59,000.00 |
| Mar 31, 2021 | 502,000.00 |
| Dec 31, 2020 | -33,000.00 |